Brandon Griffin joins Advantar Labs

Appointed as vp of sales and marketing

Advantar Labs, a contract provider of GLP and GMP research, formulation development and small-scale clinical packaging services, has added Brandon Griffin to its senior management team as vp of sales and marketing.

The San Diego, California, US-based company has an aggressive expansion plan following triple-digit growth in 2010.

Griffin will head the planning, implementation and management of Advantar’s sales and marketing strategy.

He was previously western regional vp of sales at RohnerChem, a Switzerland-based CMO, heading sales for large-scale custom synthesis of small molecules and novel monomers/biopolymers in the US.

You may also like

Media

Guardtech support staff member’s epic trek for cancer charity close to the business’ heart

The Haverhill cleanroom construction specialists donated £500 to Sarcoma UK to support their IT & Systems Manager Elliott Sheppard’s 25km trek in honour of his daughter Isobel
Research & Development

New small molecule shows promise in stopping lung cancer growth

Researchers have identified AVJ16, a drug candidate that blocks the cancer-driving protein IGF2BP1, halting tumour growth in preclinical models whilst sparing healthy cells
Finance

Genmab to acquire Merus in $8bn deal to expand late-stage pipeline

The acquisition adds breakthrough therapy petosemtamab to Genmab’s portfolio, accelerating its shift to a wholly owned model and supporting multiple new drug launches by 2027
You need to be a subscriber to read this article.
Click here to find out more.
Packaging

From box to bedside: unlocking patient-centric care with connected packaging

Pharmaceutical packaging is playing an increasing role in patient–centric care. The integration of smart 2D codes and connected digital platforms can provide a direct link between pharma manufacturers, healthcare providers and patients
Manufacturing

Quantoom Biosciences partners with Memorial Sloan Kettering Cancer Center to advance personalised mRNA cancer therapeutics

Quantoom Biosciences will use MSK's proprietary lipid nanoparticle technology, Ncapsulate QCX-002, in the development of personalised RNA-based cancer therapies, with plans to support upcoming Phase I clinical trials
Regulatory

AbbVie submits new drug application to FDA for tavapadon in Parkinson’s disease treatment

The once-daily oral dopamine D1/D5 receptor partial agonist has been supported by positive Phase III TEMPO trial results that show symptomatic improvement across the Parkinson’s disease spectrum
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Formulation meets function: addressing palatability in drug development (part II)

Part I of this article examined the critical role of palatability in patient adherence to treatment regimens, the underlying biological challenges of bitterness in medications and the innovative strategies used to create more acceptable and effective drug formulations
Subscribe now